The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2022

Filed:

Mar. 07, 2016
Applicants:

Public University Corporation Yokohama City University, Yokohama, JP;

Public University Corporation Nagoya City University, Nagoya, JP;

Pharma Foods International Co., Ltd., Kyoto, JP;

Inventors:

Mamoru Sato, Yokohama, JP;

Michiyuki Yamada, Yokohama, JP;

Satoshi Kanazawa, Nagoya, JP;

Masayoshi Toyoura, Kyoto, JP;

Yuji Shoya, Kyoto, JP;

Kenji Saito, Kyoto, JP;

Chihiro Yamazaki, Kyoto, JP;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/40 (2006.01); C12N 15/63 (2006.01); C12N 9/99 (2006.01); C12N 15/09 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); C12N 9/99 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01); C12Y 305/03015 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.


Find Patent Forward Citations

Loading…